New cervical cancer screening test could predict cell changes early

picture:

“Our hope is to be able to detect more people at risk of cervical cancer, but also that future screening should be able to predict the risk of other forms of cancer affecting women,” he says. Joachim DillnerProfessor of Infectious Epidemiology in the Department of Laboratory Medicine, Karolinska Institutet, and Director of Research and Development at Medical Diagnostics Karolinska, Karolinska University Hospital.

Study led by Professor Martin Widschwinter At the University of Innsbruck and UCL who is also visiting professor at Department of Women’s and Children’s HealthKarolinska Institutet. The research was funded in part by the European Union’s Horizon 2020 Research and Innovation Program, The Eve Appeal and the European Research Council (ERC). Several of the co-authors are patent inventors related to the WID-CIN test and some are contributors to Sola Diagnostics GmbH, which has an exclusive license to commercialize the test.

Publishing

The WID-CIN test identifies women with grade 3 intracervical neoplasia and invasive cervical cancer at risk for developing it.. James E. Barrett, Karen Sundstrom, Alison Jones, Iona Evans, Jiangrong Wang, Chiara Herzog, Joachim Dillner, Martin Widschwinter. Genomicsonline Oct 19, 2022, doi: 10.1186/s13073-022-01116-9.